[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 44 of about 44
1. Agrawal R, Misra V, Singla M, Chauhan SC, Singh PA: Intraventricular adamantinomatous craniopharyngioma in a child. Neurol India; 2008 Apr-Jun;56(2):207-9
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraventricular adamantinomatous craniopharyngioma in a child.
  • [MeSH-major] Craniopharyngioma / surgery. Pituitary Neoplasms / surgery. Ventriculoperitoneal Shunt / methods

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18688154.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] India
  •  go-up   go-down


2. Ujifuku K, Matsuo T, Takeshita T, Hayashi Y, Hayashi K, Kitagawa N, Hayashi T, Suyama K, Nagata I: Malignant transformation of craniopharyngioma associated with moyamoya syndrome. Neurol Med Chir (Tokyo); 2010;50(7):599-603
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of craniopharyngioma associated with moyamoya syndrome.
  • A 32-year-old man presented with malignant craniopharyngioma associated with moyamoya syndrome manifesting as right visual disturbance.
  • Magnetic resonance (MR) imaging revealed a parasellar mass lesion diagnosed as adamantinomatous craniopharyngioma.
  • MR imaging demonstrated tumor regrowth and bilateral occlusions of the internal carotid arteries (ICAs) with basal moyamoya phenomenon, which might have been induced by irradiation and/or tumor compression, 10 years after the initial manifestations.
  • Sufficient debulking was safely achieved via the transsphenoidal route and histological examination revealed squamous cell carcinoma, indicating malignant transformation of craniopharyngioma.
  • The tumor relapsed after only one month, so transsphenoidal tumor debulking was tried again.
  • Malignant transformation of craniopharyngioma may be included in moyamoya syndrome.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Cell Transformation, Neoplastic / pathology. Craniopharyngioma / pathology. Craniopharyngioma / surgery. Moyamoya Disease / pathology. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasms, Radiation-Induced / pathology. Neoplasms, Second Primary / pathology. Neoplasms, Second Primary / surgery. Pituitary Neoplasms / pathology. Pituitary Neoplasms / surgery. Postoperative Complications / pathology. Postoperative Complications / surgery

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20671391.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Tajima T, Sawamura Y, Ishizu K, Tsubaki J: Two children with xanthogranuloma of the sellar region. Clin Pediatr Endocrinol; 2006;15(3):85-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histological analysis of the tumor sections demonstrated granulomatous tissue with cholesterol clefts, foamy macrophages, multinucleated giant cells and no epithelial component.
  • Thus, these tumors were pathologically diagnosed as xanthogranuloma of the sellar region, different from adamantinomatous craniopharyngioma.
  • Currently, it is not clear whether xanthogranuloma is a distinct entity from adamantinomatous craniopharyingioma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24790326.001).
  • [ISSN] 0918-5739
  • [Journal-full-title] Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology
  • [ISO-abbreviation] Clin Pediatr Endocrinol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Other-IDs] NLM/ PMC4004838
  • [Keywords] NOTNLM ; craniopharyngioma / pituitary / xanthogranuloma
  •  go-up   go-down


Advertisement
4. Rakheja D, Meehan JJ, Gomez AM: Pathologic quiz case: sphenoid sinus mass in a 12-year-old girl. Infrasellar adamantinomatous craniopharyngioma. Arch Pathol Lab Med; 2005 Mar;129(3):e73-4
Genetic Alliance. consumer health - Craniopharyngioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologic quiz case: sphenoid sinus mass in a 12-year-old girl. Infrasellar adamantinomatous craniopharyngioma.
  • [MeSH-major] Ameloblastoma / diagnosis. Craniopharyngioma / diagnosis. Infratentorial Neoplasms / diagnosis. Paranasal Sinus Neoplasms / diagnosis. Sella Turcica / pathology. Sphenoid Sinus / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15737054.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Gires O: Epithelial cell adhesion molecule (EpCAM) expression in adamantinomatous craniopharyngioma. Ann Diagn Pathol; 2009 Dec;13(6):428-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial cell adhesion molecule (EpCAM) expression in adamantinomatous craniopharyngioma.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Cell Adhesion Molecules / metabolism. Craniopharyngioma / metabolism. Pituitary Neoplasms / metabolism

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Ann Diagn Pathol. 2009 Apr;13(2):82-8 [19302955.001]
  • (PMID = 19917481.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cell Adhesion Molecules; 0 / tumor-associated antigen GA733
  •  go-up   go-down


6. Liu BG, Qi ST, Pan J, Peng YP, Fang LX: [Growth of craniopharyngioma involving the third ventricular floor in relation to the hypothalamus]. Nan Fang Yi Ke Da Xue Xue Bao; 2007 Mar;27(3):377-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Growth of craniopharyngioma involving the third ventricular floor in relation to the hypothalamus].
  • OBJECTIVE: To investigate the growth of craniopharyngioma involving the third ventricular floor with regard to the hypothalamus by detecting expressions of leukocyte common antigen (CD45) and intercellular adhesion molecule (ICAM-1) in the tumor tissue.
  • METHODS: The expressions of CD45 and ICAM-1 proteins in 30 craniopharyngioma samples with third ventricular floor involvement were detected by SP immunohistochemistry.
  • RESULTS: The inflammations labeled by CD45 were identified commonly in the craniopharyngioma tissues involving the third ventricular floor.
  • The expression of ICAM-1 was mainly in the inner tumor cells and interstitial cells, but not detected in the basilar tumor cells growing toward the third ventricular floor.
  • Adamantinomatous craniopharyngiomas showed markedly higher CD45 and ICAM-1 expressions than squamous papillary tumors (P<0.05).
  • CONCLUSION: Inflammatory adhesion largely characterizes the growth of the craniopharyngioma tissues involving the third ventricular floor toward the hypothalamus without the tendency of invasion.
  • The difference in the inflammation between the two types of craniopharyngioma may affect the prognosis of the patients.
  • [MeSH-major] Craniopharyngioma / pathology. Hypothalamus / pathology. Pituitary Neoplasms / pathology. Third Ventricle
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD45 / biosynthesis. Brain Neoplasms / metabolism. Brain Neoplasms / secondary. Child. Female. Humans. Immunohistochemistry. Intercellular Adhesion Molecule-1 / biosynthesis. Male. Middle Aged. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17425998.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 126547-89-5 / Intercellular Adhesion Molecule-1; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


7. Garnett MR, Puget S, Grill J, Sainte-Rose C: Craniopharyngioma. Orphanet J Rare Dis; 2007;2:18
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Craniopharyngioma.
  • Craniopharyngiomas are benign slow growing tumours that are located within the sellar and para sellar region of the central nervous system.
  • Craniopharyngiomas are thought to arise from epithelial remnants of the craniopharyngeal duct or Rathke's pouch (adamantinomatous type) or from metaplasia of squamous epithelial cell rests that are remnants of the part of the stomadeum that contributed to the buccal mucosa (squamous papillary type).
  • Definitive diagnosis is made following histological examination of a surgical specimen.
  • The differential diagnosis includes other tumours in this region (pituitary adenoma), infectious or inflammatory processes (eosinophilic granuloma), vascular malformations (aneurysm) and congenital anomalies (Rathke's cleft cyst).
  • [MeSH-major] Craniopharyngioma / diagnosis. Craniopharyngioma / therapy. Pituitary Neoplasms / diagnosis. Pituitary Neoplasms / therapy

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Childs Nerv Syst. 1999 Nov;15(11-12):764-9 [10603020.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 May 1;44(2):255-63 [10760417.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Dec;91(12):4769-75 [16968795.001]
  • [Cites] J Neurosurg. 2007 Jan;106(1 Suppl):3-12 [17233305.001]
  • [Cites] Neurosurgery. 2001 Nov;49(5):1053-7; discussion 1057-8 [11846897.001]
  • [Cites] Acta Neurochir (Wien). 2002 Apr;144(4):403-4 [12021891.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):533-42 [12062594.001]
  • [Cites] J Neurosurg. 2002 Jul;97(1):1-2; discussion 2 [12134898.001]
  • [Cites] J Neurosurg. 2002 Jul;97(1):3-11 [12134929.001]
  • [Cites] Dev Med Child Neurol. 2004 Apr;46(4):220-9 [15077699.001]
  • [Cites] J Neurosurg. 1970 Dec;33(6):689-707 [5488801.001]
  • [Cites] Neurosurgery. 1982 Jul;11(1 Pt 1):12-5 [6287341.001]
  • [Cites] J Neurosurg. 1983 Sep;59(3):409-17 [6886754.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1984 Oct;47(10):1075-80 [6502164.001]
  • [Cites] Neurochirurgie. 1984;30(5):347-9 [6521815.001]
  • [Cites] Prog Exp Tumor Res. 1987;30:350-8 [3628817.001]
  • [Cites] Childs Nerv Syst. 1988 Apr;4(2):97-9 [3401877.001]
  • [Cites] J Neurosurg. 1990 Jul;73(1):3-11 [2352020.001]
  • [Cites] J Neurosurg. 1990 Oct;73(4):534-40 [2398383.001]
  • [Cites] Neurology. 1991 May;41(5):726-9 [2027490.001]
  • [Cites] J Neurosurg. 1991 Jun;74(6):1025-6 [2033440.001]
  • [Cites] Neurol Clin. 1991 May;9(2):453-65 [1944109.001]
  • [Cites] J Neurosurg. 1992 Jan;76(1):47-52 [1727168.001]
  • [Cites] Pediatr Neurosurg. 1994;21 Suppl 1:11-7 [7841069.001]
  • [Cites] Neurosurgery. 1994 Dec;35(6):1001-10; discussion 1010-1 [7885544.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Jul;81(7):2734-7 [8675604.001]
  • [Cites] J Neurosurg. 1996 Jul;85(1):73-81 [8683285.001]
  • [Cites] J Neurosurg. 1998 Oct;89(4):547-51 [9761047.001]
  • [Cites] J Neurosurg. 1999 Feb;90(2):237-50 [9950494.001]
  • [Cites] Pediatr Hematol Oncol. 2005 Mar;22(2):89-101 [15804994.001]
  • [Cites] Neurosurg Focus. 2005 Jun 15;18(6A):E6 [16048292.001]
  • [Cites] Childs Nerv Syst. 2005 Aug;21(8-9):729-46 [16044343.001]
  • [Cites] Childs Nerv Syst. 2005 Aug;21(8-9):808-16 [16075214.001]
  • [Cites] Childs Nerv Syst. 2005 Aug;21(8-9):691-5 [16078079.001]
  • [Cites] Childs Nerv Syst. 2005 Aug;21(8-9):719-24 [16133276.001]
  • [Cites] J Pediatr Endocrinol Metab. 2006 Apr;19 Suppl 1:289-93 [16700303.001]
  • [Cites] J Pediatr Endocrinol Metab. 2006 Apr;19 Suppl 1:299-319 [16700305.001]
  • [Cites] J Pediatr Endocrinol Metab. 2006 Apr;19 Suppl 1:325-7 [16700307.001]
  • [Cites] J Pediatr Endocrinol Metab. 2006 Apr;19 Suppl 1:329-35 [16700308.001]
  • [Cites] J Pediatr Endocrinol Metab. 2006 Apr;19 Suppl 1:337-40 [16700309.001]
  • [Cites] J Pediatr Endocrinol Metab. 2006 Apr;19 Suppl 1:389-94 [16700315.001]
  • [Cites] J Pediatr Endocrinol Metab. 2006 Apr;19 Suppl 1:407-12 [16700318.001]
  • [Cites] Endocr Rev. 2006 Jun;27(4):371-97 [16543382.001]
  • (PMID = 17425791.001).
  • [ISSN] 1750-1172
  • [Journal-full-title] Orphanet journal of rare diseases
  • [ISO-abbreviation] Orphanet J Rare Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 43
  • [Other-IDs] NLM/ PMC1855047
  •  go-up   go-down


8. Yamada Y, Haraoka J, Akimoto J: Ectopic recurrence of craniopharyngioma. Neurol Med Chir (Tokyo); 2006 Dec;46(12):598-600
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ectopic recurrence of craniopharyngioma.
  • A 27-year-old woman presented with ectopic recurrence manifesting as an asymptomatic mass in the left frontal convexity 5 years after subtotal removal of suprasellar craniopharyngioma through a right orbitozygomatic craniotomy.
  • The histological diagnoses of both lesions were adamantinomatous type craniopharyngioma with MIB-1 indexes of 4.2% and 7.4%.
  • Craniopharyngioma is a benign tumor, and ectopic recurrence is rare.
  • [MeSH-major] Craniopharyngioma / pathology. Frontal Lobe / pathology. Pituitary Neoplasms / pathology
  • [MeSH-minor] Adolescent. Female. Humans. Neoplasm Invasiveness. Recurrence

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17185886.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


9. Powers CJ, New KC, McLendon RE, Friedman AH, Fuchs HE: Cerebellopontine angle craniopharyngioma: case report and literature review. Pediatr Neurosurg; 2007;43(2):158-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebellopontine angle craniopharyngioma: case report and literature review.
  • The authors report an unusual case of adamantinomatous craniopharyngioma occurring in isolation in the cerebellopontine angle of a 12-year-old female.
  • MRI revealed a left cerebellopontine angle tumor without connection to the suprasellar space.
  • Following near-total resection, histological review confirmed the lesion as an adamantinomatous craniopharyngioma.
  • This is only the third published report of craniopharyngioma occurring in isolation in the cerebellopontine angle.
  • [MeSH-major] Cerebellar Neoplasms / surgery. Cerebellopontine Angle / surgery. Craniopharyngioma / surgery. Pituitary Neoplasms / surgery
  • [MeSH-minor] Calcinosis / diagnosis. Calcinosis / pathology. Calcinosis / surgery. Cerebrospinal Fluid Shunts. Child. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Hydrocephalus / etiology. Hydrocephalus / surgery. Magnetic Resonance Imaging. Microsurgery. Neoplasm, Residual / diagnosis. Neoplasm, Residual / radiotherapy. Neurologic Examination. Postoperative Complications / diagnosis. Postoperative Complications / radiotherapy. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 S. Karger AG, Basel.
  • (PMID = 17337933.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 17
  •  go-up   go-down


10. Karavitaki N, Scheithauer BW, Watt J, Ansorge O, Moschopoulos M, Llaguno AV, Wass JA: Collision lesions of the sella: co-existence of craniopharyngioma with gonadotroph adenoma and of Rathke's cleft cyst with corticotroph adenoma. Pituitary; 2008;11(3):317-23
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision lesions of the sella: co-existence of craniopharyngioma with gonadotroph adenoma and of Rathke's cleft cyst with corticotroph adenoma.
  • Most contributions include a pituitary adenoma or a cyst/cystic tumor, particularly a Rathke cleft cyst.
  • The association of craniopharyngioma with an adenoma is particularly rare.
  • Herein, we report two collision lesions, including a gonadotroph adenoma with adamantinomatous craniopharyngioma and a corticotroph adenoma with Rathke's cleft cyst.
  • [MeSH-major] ACTH-Secreting Pituitary Adenoma / complications. Adenoma / complications. Central Nervous System Cysts / complications. Corticotrophs / pathology. Craniopharyngioma / complications. Gonadotrophs / pathology. Pituitary Neoplasms / complications. Sella Turcica / pathology

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] No Shinkei Geka. 2005 Aug;33(8):797-803 [16095210.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1986 Nov;49(11):1305-7 [3794737.001]
  • [Cites] No To Shinkei. 1969 Dec;21(12):1326-9 [5395295.001]
  • [Cites] Arch Pathol. 1970 Nov;90(5):444-50 [5476241.001]
  • [Cites] Am J Clin Pathol. 2003 Nov;120(5):732-6 [14608900.001]
  • [Cites] J Clin Invest. 2003 Dec;112(11):1603-18 [14660734.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1959 Feb;12(2):199-205 [13633216.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):1997-2001 [12466115.001]
  • [Cites] Arch Pathol Lab Med. 1994 May;118(5):562-5 [8192565.001]
  • [Cites] Arch Dis Child. 1987 Oct;62(10):1077-8 [2823728.001]
  • [Cites] Endocr Rev. 2006 Jun;27(4):371-97 [16543382.001]
  • [Cites] J Pathol. 2004 Jul;203(3):814-21 [15221941.001]
  • [Cites] JAMA. 1978 Aug 4;240(5):471-3 [660898.001]
  • [Cites] J Neurosurg. 1966 Aug;25(2):199-204 [5296495.001]
  • [Cites] Endocr Rev. 1998 Dec;19(6):798-827 [9861546.001]
  • [Cites] Intern Med J. 2004 Sep-Oct;34(9-10):573-6 [15482272.001]
  • [Cites] Cancer. 1978 Jan;41(1):337-43 [626939.001]
  • [Cites] No Shinkei Geka. 1984 Jun;12(7):833-8 [6483092.001]
  • [Cites] Anat Rec. 1951 Feb;109(2):217-31 [14811058.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1983;399(1):49-59 [6299000.001]
  • [Cites] Acta Neuropathol. 2005 Jun;109(6):589-97 [15891929.001]
  • [Cites] No Shinkei Geka. 1987 Dec;15(12):1313-8 [3448501.001]
  • [Cites] Mayo Clin Proc. 1989 Sep;64(9):1077-84 [2811485.001]
  • [Cites] No Shinkei Geka. 1986 Mar;14 (3 Suppl):435-40 [3703147.001]
  • [Cites] Endocrinology. 2002 Nov;143(11):4429-36 [12399440.001]
  • [Cites] Neuroradiology. 2001 Sep;43(9):755-9 [11594426.001]
  • [Cites] Endocr Pathol. 2001 Summer;12(2):125-36 [11579678.001]
  • [Cites] J Neurosurg. 2004 Jan;100(1):33-40 [14743909.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1983 Nov;56(5):502-11 [6196702.001]
  • [Cites] Surg Neurol. 1989 May;31(5):381-6 [2711312.001]
  • [Cites] J Neurosurg. 2003 Jan;98(1):162-4 [12546365.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1975 Aug;38(8):782-6 [1185198.001]
  • [Cites] Neurosurgery. 1987 Sep;21(3):371-7 [3670583.001]
  • [Cites] J Neurosurg. 1966 Jan;24(1):77-81 [5903300.001]
  • [Cites] Neurosurgery. 1985 Oct;17(4):657-9 [4058703.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Apr;62(4):397-409 [15807869.001]
  • [Cites] J Pathol. 1971 Mar;103(3):185-7 [5567175.001]
  • [Cites] Br J Neurosurg. 1995;9(1):51-5 [7786427.001]
  • [Cites] J Neurooncol. 2005 Jul;73(3):205-9 [15980970.001]
  • [Cites] Cancer. 1972 Feb;29(2):423-30 [5013542.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jul;82(7):2357-62 [9215319.001]
  • [Cites] Pediatr Neurosurg. 1994;21 Suppl 1:2-10 [7841074.001]
  • [Cites] J Neurosurg. 1994 Jun;80(6):1018-25 [8189257.001]
  • [Cites] J Neurosurg. 1998 Oct;89(4):547-51 [9761047.001]
  • [Cites] No Shinkei Geka. 1987 Sep;15(9):999-1003 [3320806.001]
  • [Cites] Zh Vopr Neirokhir Im N N Burdenko. 1981 Nov-Dec;(6):52-4 [7336839.001]
  • [Cites] J Neurosurg. 2005 Apr;102(3 Suppl):318-21 [15881759.001]
  • [Cites] J Pathol Bacteriol. 1955 Jan-Apr;69(1-2):141-5 [13243181.001]
  • [Cites] Arch Pathol. 1960 Sep;70:293-9 [13850582.001]
  • [Cites] Cancer. 1976 Apr;37(4):1944-52 [1260697.001]
  • [Cites] Neurosurgery. 2000 Feb;46(2):291-302; discussion 302-5 [10690718.001]
  • [Cites] Cancer Genet Cytogenet. 1992 Mar;59(1):12-9 [1313329.001]
  • [Cites] Surg Neurol. 1994 Aug;42(2):112-6 [8091286.001]
  • [Cites] Cancer Genet Cytogenet. 1992 Jun;60(2):212-3 [1606570.001]
  • [Cites] Pituitary. 2004;7(1):39-44 [15638297.001]
  • [Cites] Endocr Pathol. 2002 Summer;13(2):157-65 [12165665.001]
  • [Cites] Intern Med. 1997 Feb;36(2):107-12 [9099592.001]
  • [Cites] Acta Neuropathol. 1992;83(2):211-5 [1557952.001]
  • [Cites] J Neurosurg. 1988 Oct;69(4):620-3 [3418397.001]
  • [Cites] Neurosci Lett. 2001 Sep 7;310(1):5-8 [11524144.001]
  • [Cites] Neurol Med Chir (Tokyo). 1993 Sep;33(9):643-50 [7505406.001]
  • (PMID = 17917812.001).
  • [ISSN] 1386-341X
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 65
  •  go-up   go-down


11. Lermen O, Frank S, Hassler W: Postoperative spinal recurrence of craniopharyngioma. Acta Neurochir (Wien); 2010 Feb;152(2):309-11; discussion 311
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative spinal recurrence of craniopharyngioma.
  • PURPOSE: Remote recurrence of craniopharyngioma is an unusual postoperative complication.
  • METHODS: A 49-year-old male had been operated on twice for a suprasellar craniopharyngioma in September 1999 and February 2003.
  • From August 2003, he noted progressive low-back pain followed by ischialgia along the right S1 dermatome, which was symptomatic of an intradural tumor at the level of the first sacral segment.
  • RESULTS: Total resection was performed and the tumor was histologically confirmed to be an adamantinomatous craniopharyngioma.
  • CONCLUSIONS: We report the first case of remote spinal recurrence of adamantinomatous craniopharyngioma.
  • One must bear in mind this rare complication in craniopharyngioma patients and underline the importance of long-term follow-up.
  • [MeSH-major] Craniopharyngioma / secondary. Neoplasm Metastasis / pathology. Neoplasm Seeding. Pituitary Neoplasms / pathology. Spinal Neoplasms / secondary
  • [MeSH-minor] Choristoma / pathology. Choristoma / surgery. Humans. Laminectomy. Low Back Pain / etiology. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neurosurgical Procedures. Polyradiculopathy / etiology. Polyradiculopathy / pathology. Polyradiculopathy / surgery. Sacrum / pathology. Sacrum / surgery. Sciatica / etiology. Spinal Canal / pathology. Spinal Canal / surgery. Spinal Nerve Roots / pathology. Spinal Nerve Roots / physiopathology. Spinal Nerve Roots / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19838829.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


12. Sargis RM, Wollmann RL, Pytel P: A 59 year-old man with sellar lesion. Brain Pathol; 2009 Jan;19(1):161-2
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pathologic examination revealed a tumor with two distinct cell populations.
  • The majority of the tumor showed typical pituitary gonadotroph adenoma morphology and staining.
  • Diffusely scattered throughout this tumor were nests of epithelial cells with an appearance typical of adamantinomatous craniopharyngioma and that were proliferating by Ki-67.
  • Moreover, their diffuse distribution within the adenoma portion of the tumor suggests that these areas arose from within the adenoma where squamous rests are not observed.
  • While pituitary adenomas juxtaposed to craniopharyngiomas have been reported, these cases have consisted of distinct masses unlike the intimately admixed tumor described in this case.
  • Moreover, all previous reports of craniopharyngiomas with pituitary adenoma have consisted of prolactinomas.
  • This is the first reported case of a craniopharyngioma with gonadotroph adenoma.
  • [MeSH-major] Craniopharyngioma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Pituitary Neoplasms / diagnosis. Sella Turcica

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19076783.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


13. Moshkin O, Scheithauer BW, Syro LV, Velasquez A, Horvath E, Kovacs K: Collision tumors of the sella: craniopharyngioma and silent pituitary adenoma subtype 3: case report. Endocr Pathol; 2009;20(1):50-5
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision tumors of the sella: craniopharyngioma and silent pituitary adenoma subtype 3: case report.
  • The association of a craniopharyngioma and a pituitary adenoma is rare.
  • Herein, we report the first case of an association between craniopharyngioma and silent pituitary adenoma subtype 3.
  • It involved a 12-year-old boy who underwent a frontal craniotomy with surgical removal of a calcified sellar tumor.
  • Histology revealed an adamantinomatous craniopharyngioma; however, by electron microscopy, there was conclusive evidence of adenoma cells showing the ultrastructural features of silent pituitary adenoma subtype 3.
  • [MeSH-major] Adenoma / ultrastructure. Craniopharyngioma / ultrastructure. Neoplasms, Multiple Primary / pathology. Pituitary Neoplasms / ultrastructure

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurol Neurosurg Psychiatry. 1986 Nov;49(11):1305-7 [3794737.001]
  • [Cites] No To Shinkei. 1969 Dec;21(12):1326-9 [5395295.001]
  • [Cites] Zh Vopr Neirokhir Im N N Burdenko. 1989 Mar-Apr;(2):26-9 [2750397.001]
  • [Cites] Pathology. 2002 Feb;34(1):57-60 [11902447.001]
  • [Cites] Pituitary. 2008;11(3):317-23 [17917812.001]
  • [Cites] No Shinkei Geka. 1987 Dec;15(12):1313-8 [3448501.001]
  • [Cites] Radiol Clin North Am. 1999 Jan;37(1):101-21, x [10026732.001]
  • [Cites] Exp Clin Endocrinol. 1993;101(5):283-9 [8299704.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Jul;61(1):26-30 [15212641.001]
  • [Cites] Ultrastruct Pathol. 2005 Nov-Dec;29(6):511-24 [16316952.001]
  • [Cites] J Neurosurg. 1991 Feb;74(2):243-7 [1988594.001]
  • [Cites] J Clin Endocrinol Metab. 1988 Jun;66(6):1111-8 [3372677.001]
  • [Cites] Pituitary. 1999 May;1(3-4):243-50 [11081204.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Apr;62(4):397-409 [15807869.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Dec;84(12):4317-23 [10599681.001]
  • [Cites] J Pathol. 1971 Mar;103(3):185-7 [5567175.001]
  • [Cites] J Neurosurg. 1998 Oct;89(4):547-51 [9761047.001]
  • [Cites] Zh Vopr Neirokhir Im N N Burdenko. 1981 Nov-Dec;(6):52-4 [7336839.001]
  • [Cites] Neurosurgery. 1992 Nov;31(5):840-9; discussion 849 [1331847.001]
  • [Cites] J Neurosurg. 1988 Oct;69(4):620-3 [3418397.001]
  • (PMID = 19238590.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


14. Campanini ML, Colli LM, Paixao BM, Cabral TP, Amaral FC, Machado HR, Neder LS, Saggioro F, Moreira AC, Antonini SR, de Castro M: CTNNB1 gene mutations, pituitary transcription factors, and MicroRNA expression involvement in the pathogenesis of adamantinomatous craniopharyngiomas. Horm Cancer; 2010 Aug;1(4):187-96
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CTNNB1 gene mutations, pituitary transcription factors, and MicroRNA expression involvement in the pathogenesis of adamantinomatous craniopharyngiomas.
  • Genes involved in formation/development of the adenohypophysis, CTNNB1 gene, and microRNAs might be implicated in the craniopharyngioma pathogenesis.
  • The objective of this study is to perform the molecular analysis of HESX1, PROP1, POU1F1, and CTNNB1 genes and evaluate a panel of miRNA expression in craniopharyngioma.
  • The study included 16 patients with adamantinomatous craniopharyngioma (nine children and seven adults; eight females and eight males; 6-55 years, median 15.5 years).
  • DNA, RNA, and cDNA were obtained from craniopharyngioma and normal pituitaries.
  • We found no mutations in HESX1, PROP1, and POU1F1 genes and four polymorphisms in PROP1 gene which were in Hardy-Weinberg equilibrium and had similar allelic frequencies in craniopharyngioma and controls.
  • We observed hyperexpression of miR-150 (1.7-fold); no different expression of miR-16-1, miR-21, and miR23a; and an underexpression of miR-141, let-7a, miR-16, miR-449, miR-145, miR-143, miR-23b, miR-15a, and miR-24-2 (ranging from -7.5 to -2.5-fold; p = 0.02) in craniopharyngioma.
  • There was no association between tumor size or the recurrence and the presence of CTNNB1mutations. miR-16 and miR-141 were underexpressed in craniopharyngioma presenting CTNNB1 mutations. miR-23a and miR24-2 were hyperexpressed in patients who underwent only one surgery.
  • Mutations or polymorphisms in pituitary transcription factors are unlikely to contribute to the adamantinomatous craniopharyngioma pathogenesis, differently of CTNNB1 mutations.
  • Our data suggest the potential involvement of the deregulation of miRNA expression in the craniopharyngioma pathogenesis and outcome and also that the miRNA could modulate the Wnt signaling pathway in craniopharyngioma tumorigenesis.
  • [MeSH-major] Craniopharyngioma / genetics. MicroRNAs / genetics. Pituitary Neoplasms / genetics. Transcription Factors / genetics. beta Catenin / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Physiol. 2005 Jul;204(1):280-5 [15648093.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Jan;94(1):320-3 [18840638.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1595-603 [17122517.001]
  • [Cites] Am J Clin Pathol. 2003 Nov;120(5):732-6 [14608900.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):1997-2001 [12466115.001]
  • [Cites] Childs Nerv Syst. 2005 Aug;21(8-9):622-7 [15965669.001]
  • [Cites] Arq Bras Endocrinol Metabol. 2009 Feb;53(1):31-9 [19347183.001]
  • [Cites] Endocr Rev. 2006 Jun;27(4):371-97 [16543382.001]
  • [Cites] J Pathol. 2004 Jul;203(3):814-21 [15221941.001]
  • [Cites] J Cell Physiol. 2007 Feb;210(2):370-7 [17111382.001]
  • [Cites] Cell. 2006 May 5;125(3):593-605 [16678101.001]
  • [Cites] Genes Dev. 2001 Dec 1;15(23 ):3193-207 [11731482.001]
  • [Cites] Acta Neuropathol. 2005 Jun;109(6):589-97 [15891929.001]
  • [Cites] Development. 1998 Dec;125(23):4835-40 [9806931.001]
  • [Cites] Brain Pathol. 2009 Jul;19(3):357-64 [18540944.001]
  • [Cites] Mol Endocrinol. 1996 Dec;10(12):1570-81 [8961267.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1787-90 [9065402.001]
  • [Cites] Annu Rev Cell Dev Biol. 2004;20:781-810 [15473860.001]
  • [Cites] Obesity (Silver Spring). 2011 Jan;19(1):36-42 [20379145.001]
  • [Cites] Acta Neuropathol. 2010 May;119(5):631-9 [20131060.001]
  • [Cites] Nucleic Acids Res. 2005 Mar 01;33(4):1290-7 [15741182.001]
  • [Cites] Cancer Res. 2009 Apr 15;69(8):3278-82 [19351815.001]
  • [Cites] Acta Neuropathol. 1998 Mar;95(3):291-6 [9542595.001]
  • [Cites] J Neurosurg. 1999 Feb;90(2):237-50 [9950494.001]
  • [Cites] Development. 1996 Jan;122(1):41-52 [8565852.001]
  • [Cites] J Neurosurg. 2003 Jan;98(1):162-4 [12546365.001]
  • [Cites] J Neurosurg. 1990 Jul;73(1):12-7 [2352012.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Apr;62(4):397-409 [15807869.001]
  • [Cites] Nat Genet. 1998 Jun;19(2):125-33 [9620767.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Dec 15;189(2):851-5 [1472057.001]
  • [Cites] J Pediatr. 2001 Nov;139(5):754 [11713462.001]
  • [Cites] Curr Opin Pediatr. 2007 Aug;19(4):471-9 [17630614.001]
  • [Cites] J Clin Endocrinol Metab. 2004 May;89(5):2200-6 [15126542.001]
  • [Cites] Dev Biol. 2007 Feb 1;302(1):1-12 [16989803.001]
  • [Cites] Clin Endocrinol (Oxf). 1995 May;42(5):467-73 [7621564.001]
  • [Cites] Neurosurgery. 1994 Dec;35(6):1001-10; discussion 1010-1 [7885544.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Mar;84(3):942-5 [10084575.001]
  • [Cites] Arch Pathol. 1960 Sep;70:293-9 [13850582.001]
  • [Cites] Nature. 1996 Nov 28;384(6607):327-33 [8934515.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2003 Feb;74(2):260-1 [12531965.001]
  • [Cites] Annu Rev Pathol. 2009;4:199-227 [18817506.001]
  • [Cites] Neurosci Lett. 2001 Sep 7;310(1):5-8 [11524144.001]
  • [Cites] Nature. 1990 Oct 11;347(6293):528-33 [1977085.001]
  • (PMID = 21761366.001).
  • [ISSN] 1868-8500
  • [Journal-full-title] Hormones & cancer
  • [ISO-abbreviation] Horm Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / HESX1 protein, human; 0 / Homeodomain Proteins; 0 / MicroRNAs; 0 / POU1F1 protein, human; 0 / Prophet of Pit-1 protein; 0 / Transcription Factor Pit-1; 0 / Transcription Factors; 0 / beta Catenin
  •  go-up   go-down


15. Pekmezci M, Louie J, Gupta N, Bloomer MM, Tihan T: Clinicopathological characteristics of adamantinomatous and papillary craniopharyngiomas: University of California, San Francisco experience 1985-2005. Neurosurgery; 2010 Nov;67(5):1341-9; discussion 1349
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological characteristics of adamantinomatous and papillary craniopharyngiomas: University of California, San Francisco experience 1985-2005.
  • BACKGROUND: Craniopharyngiomas are rare epithelial tumors that are presumed to arise from the remnants of Rathke's pouch.
  • OBJECTIVE: This study was designed to evaluate the outcome characteristics of craniopharyngiomas treated in a single institution and to determine whether the adamantinomatous craniopharyngioma should be considered more aggressive than a World Health Organization (WHO) grade I neoplasm.
  • METHODS: We identified all patients with craniopharyngioma given their diagnoses at University of California, San Francisco in a 20-year period and performed a retrospective analysis of clinicopathological and outcome characteristics.
  • Sixty-nine tumors were adamantinomatous, 9 were papillary, and 2 were unclassified.
  • All pediatric tumors were adamantinomatous.
  • CONCLUSION: Adamantinomatous craniopharyngioma is a locally aggressive neoplasm with a significant rate of recurrence.
  • This is not in keeping with the current designation of a WHO grade I neoplasm.
  • Given the high numbers of "silent" defects, formal visual field testing should be performed in all patients with craniopharyngiomas.
  • [MeSH-major] Craniopharyngioma / mortality. Craniopharyngioma / surgery. Neoplasm Recurrence, Local / mortality. Pituitary Neoplasms / mortality. Pituitary Neoplasms / surgery. Postoperative Complications / mortality

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20871436.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


16. Schmalisch K, Beschorner R, Psaras T, Honegger J: Postoperative intracranial seeding of craniopharyngiomas--report of three cases and review of the literature. Acta Neurochir (Wien); 2010 Feb;152(2):313-9; discussion 319
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative intracranial seeding of craniopharyngiomas--report of three cases and review of the literature.
  • PURPOSE: Seeding of craniopharyngioma has been rarely reported.
  • METHODS: The first patient was a 13-year-old boy who had initially undergone radical excision of a suprasellar and retrosellar craniopharyngioma by a right pterional approach.
  • Postoperative MRI showed no evidence of residual tumor.
  • Two years later, MRI revealed a local recurrence and in addition a separated cystic tumor on the right side adjacent to the middle cerebral artery consistent with seeding along the surgical route.
  • On histopathological examination, both, the local recurrent tumor and the distant deposit turned out to be adamantinomatous craniopharyngiomas.
  • The second patient was a 27-year-old woman who was operated on for the first time via a right pterional and 1 year later for a recurrent craniopharyngioma via a transsphenoidal approach.
  • This deposit in the operative pathway was found to be an adamantinomatous craniopharyngioma, as was the initial tumor.
  • The recent control MRT revealed a right parietal intracranial tumor with peripheral contrast enhancement, which was located distant to the former craniotomy.
  • The tumor was removed and histopathological examination revealed an adamantinomatous craniopharyngioma in accordance with the initial tumor.
  • CONCLUSION: Although craniopharyngiomas exhibit a benign histopathological pattern, cerebrospinal fluid seeding along the surgical route or along the CSF pathways has been observed.
  • Ectopic recurrence of craniopharyngioma suggests that meticulous protection of the whole surgical field and careful handling of the tumor during the operation are required.
  • [MeSH-major] Brain Neoplasms / secondary. Craniopharyngioma / secondary. Neoplasm Metastasis / pathology. Neoplasm Seeding. Pituitary Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Craniotomy. Female. Frontal Bone / pathology. Frontal Bone / surgery. Humans. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Parietal Bone / pathology. Parietal Bone / surgery. Reoperation. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19859655.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Austria
  • [Number-of-references] 31
  •  go-up   go-down


17. Ragel BT, Bishop FS, Couldwell WT: Recurrent infrasellar clival craniopharyngioma. Acta Neurochir (Wien); 2007;149(7):729-30; discussion 730
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent infrasellar clival craniopharyngioma.
  • The patient is a 44-year-old man who underwent resection of a posterior nasopharynx tumor 12 years earlier via left lateral rhinotomy approach.
  • The final pathological analysis indicated the tumor was a craniopharyngioma, and the patient subsequently underwent focal radiation.
  • Magnetic resonance imaging revealed a clival mass, separate from the sella turcica, with imaging characteristics concerning for chordoma or primary bone tumor (Fig. 1).
  • The final pathological results indicated the tumor was adamantinomatous craniopharyngioma.
  • [MeSH-major] Cranial Fossa, Posterior / pathology. Craniopharyngioma / pathology. Pituitary Neoplasms / pathology
  • [MeSH-minor] Adult. Humans. Magnetic Resonance Imaging. Male. Nasopharynx / pathology. Nasopharynx / physiopathology. Nasopharynx / surgery. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Pituitary Gland / pathology. Radiotherapy. Sella Turcica / pathology

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17533510.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


18. Caceres A, Reitman AJ, Tomita T: Craniopharyngioma and Cushing disease: case report. J Neurosurg; 2005 Apr;102(3 Suppl):318-21
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Craniopharyngioma and Cushing disease: case report.
  • Craniopharyngioma is a common sellar region tumor occurring in children.
  • Patients with craniopharyngioma commonly present with visual deficits and hydrocephalus.
  • The authors present the case of a child who presented with short stature and clinical evidence of Cushing disease (CD) associated with a suprasellar tumor.
  • The patient underwent insertion of an Ommaya reservoir into the tumor's cystic portion.
  • After adequate decompression of the tumor, the patient underwent total resection.
  • The tumor pathology was compatible with an adamantinomatous craniopharyngioma and immunohistochemical studies failed to show staining for ACTH.
  • [MeSH-major] Central Nervous System Cysts / surgery. Craniopharyngioma / surgery. Pituitary ACTH Hypersecretion / surgery. Pituitary Neoplasms / surgery

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15881759.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-60-2 / Adrenocorticotropic Hormone
  •  go-up   go-down


19. Frangou EM, Tynan JR, Robinson CA, Ogieglo LM, Vitali AM: Metastatic craniopharyngioma: case report and literature review. Childs Nerv Syst; 2009 Sep;25(9):1143-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic craniopharyngioma: case report and literature review.
  • BACKGROUND: Distant spread of craniopharyngioma is a rare but important complication.
  • We describe a rare case of metastatic leptomeningeal craniopharyngioma as a result of dissemination along CSF pathways in a child.
  • CASE PRESENTATION: A 14-year-old male was diagnosed with metastatic craniopharyngioma on routine follow-up imaging after multiple surgeries and radiation for locally recurrent craniopharyngioma.
  • Histopathology confirmed adamantinomatous craniopharyngioma.
  • DISCUSSION: A review of reported cases suggests that leptomeningeal implantation may be an important step in metastases of craniopharyngioma, although the mechanism is poorly understood.
  • Attention to tumor spillage at the time of surgery may be important in preventing distant recurrences.
  • [MeSH-major] Brain Neoplasms. Craniopharyngioma / secondary. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1991 Apr;74(4):653-5 [2002381.001]
  • [Cites] Neurosurgery. 2002 Mar;50(3):639-44; discussion 644-5 [11841735.001]
  • [Cites] Pediatr Neurosurg. 1995;22(4):210-3 [7619722.001]
  • [Cites] Childs Nerv Syst. 2002 Oct;18(9-10):468-73 [12382167.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Sep;17(8):1441-2 [8883638.001]
  • [Cites] Surg Neurol. 2006 Oct;66(4):437-40; discussion 440 [17015135.001]
  • [Cites] J Neurosurg. 1990 Jul;73(1):3-11 [2352020.001]
  • [Cites] Br J Neurosurg. 2001 Dec;15(6):511-3 [11814004.001]
  • [Cites] Acta Neurochir (Wien). 1997;139(4):379-80 [9202784.001]
  • [Cites] J Neurosurg. 2007 Jul;107(1):178-80 [17639891.001]
  • [Cites] Pediatr Neurosurg. 2002 Oct;37(4):210-6 [12372916.001]
  • [Cites] J Neurosurg. 2001 Apr;94(4):617-20 [11302661.001]
  • [Cites] Pediatr Neurosurg. 1994;21 Suppl 1:39-43 [7841077.001]
  • [Cites] Neurosurgery. 2009 Feb;64(2):E382-3; discussion E383 [19190442.001]
  • [Cites] Neuro Oncol. 2002 Apr;4(2):123-8 [11916504.001]
  • [Cites] J Neurosurg. 1992 Nov;77(5):804-7 [1403127.001]
  • [Cites] Lab Invest. 2002 Nov;82(11):1493-502 [12429809.001]
  • [Cites] Korean J Radiol. 2004 Jan-Mar;5(1):72-4 [15064562.001]
  • [Cites] Neurosurgery. 1994 Feb;34(2):346-9; discussion 349 [8177397.001]
  • [Cites] J Neurosurg. 1999 Apr;90(4):796 [10193630.001]
  • [Cites] Neurol Med Chir (Tokyo). 2006 Dec;46(12):598-600 [17185886.001]
  • [Cites] Neurol Med Chir (Tokyo). 2002 Jun;42(6):268-71 [12116534.001]
  • [Cites] Minim Invasive Neurosurg. 2008 Jun;51(3):165-8 [18521788.001]
  • [Cites] J Clin Neurosci. 2006 Apr;13(3):405 [16540322.001]
  • [Cites] Neurosurgery. 2001 Apr;48(4):933-5; discussion 935-6 [11322455.001]
  • [Cites] Pediatr Neurosurg. 2007;43(2):158-63 [17337933.001]
  • [Cites] Acta Neurochir (Wien). 2002 Nov;144(11):1221-4 [12434179.001]
  • [Cites] J Clin Neurosci. 2005 Apr;12(3):307-9 [15851090.001]
  • [Cites] Childs Nerv Syst. 1992 Feb;8(1):56-8 [1576611.001]
  • [Cites] Surg Neurol. 2007 Jul;68(1):96-8 [17586238.001]
  • [Cites] Neurochirurgie. 2002 Sep;48(4):345-50 [12407320.001]
  • [Cites] Neurosurgery. 1994 Dec;35(6):1001-10; discussion 1010-1 [7885544.001]
  • [Cites] AJNR Am J Neuroradiol. 1999 Jun-Jul;20(6):1059-60 [10445444.001]
  • [Cites] Cancer Treat Res. 2005;125:17-30 [16211881.001]
  • [Cites] AJNR Am J Neuroradiol. 1988 Mar-Apr;9(2):406-7 [3128093.001]
  • [Cites] J Neurooncol. 2006 Sep;79(2):191-5 [16850111.001]
  • [Cites] Br J Neurosurg. 1996 Dec;10(6):613-5 [9115662.001]
  • [Cites] Pediatr Neurosurg. 2004 Sep-Oct;40(5):230-3 [15687737.001]
  • (PMID = 19517118.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 39
  •  go-up   go-down


20. Bernstein M, Khu KJ: Is there too much variability in technical neurosurgery decision-making? Virtual Tumour Board of a challenging case. Acta Neurochir (Wien); 2009 Apr;151(4):411-2; discussion 412-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there too much variability in technical neurosurgery decision-making? Virtual Tumour Board of a challenging case.
  • The pathology was adamantinomatous craniopharyngioma.
  • [MeSH-major] Craniopharyngioma / surgery. Craniotomy / methods. Evidence-Based Medicine / standards. Neurosurgical Procedures / methods. Pituitary Neoplasms / surgery. Referral and Consultation / standards

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19255714.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


21. Oikonomou E, Barreto DC, Soares B, De Marco L, Buchfelder M, Adams EF: Beta-catenin mutations in craniopharyngiomas and pituitary adenomas. J Neurooncol; 2005 Jul;73(3):205-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beta-catenin mutations in craniopharyngiomas and pituitary adenomas.
  • Craniopharyngiomas and pituitary adenomas are both tumors of the hypothalamic and pituitary region, respectively that are frequently associated with endocrine defects either because of direct involvement of hormone producing cells (most pituitary tumors) or because of secondary defects due to disturbance of hypothalamic function (some pituitary tumors and craniopharyngiomas).
  • Some studies suggest that mutant beta-catenin gene cells in craniopharyngiomas and pituitary adenomas contribute to their tumorigenesis.
  • Sequenced PCR products for possible beta-catenin gene mutations showed a total of 7/43 alterations in adamantinomatous craniopharyngioma-derived DNA samples.
  • None of the 22 pituitary adenomas and the eight papillary craniopharyngiomas analyzed presented any sequence alterations.
  • These findings demonstrate an association between beta-catenin gene alterations and craniopharyngiomas of the adamantinomatous type.
  • Since this gene product is involved with development, these results suggest that beta-catenin mutations may contribute to the initiation and subsequent growth of congenital craniopharyngiomas.
  • [MeSH-major] Adenoma / genetics. Craniopharyngioma / genetics. Cytoskeletal Proteins / genetics. Pituitary Neoplasms / genetics. Trans-Activators / genetics

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2002 Dec;161(6):1997-2001 [12466115.001]
  • [Cites] Endocrinologie. 1990 Apr-Jun;28(2):67-72 [2293330.001]
  • [Cites] Cancer. 2001 Jan 1;91(1):42-8 [11148558.001]
  • [Cites] Genes Dev. 2000 Aug 1;14 (15):1837-51 [10921899.001]
  • [Cites] Cancer Sci. 2003 Mar;94(3):225-9 [12824913.001]
  • [Cites] Bioessays. 1989 Oct;11(4):88-91 [2695079.001]
  • [Cites] Semin Diagn Pathol. 1986 Feb;3(1):69-82 [3039632.001]
  • [Cites] Science. 1991 Mar 22;251(5000):1451-5 [2006419.001]
  • [Cites] Development. 1998 Nov;125(21):4225-34 [9753677.001]
  • [Cites] J Embryol Exp Morphol. 1975 Oct;34(2):311-25 [1194833.001]
  • [Cites] Bioessays. 1999 Dec;21(12):1021-30 [10580987.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Feb 16;268(2):243-8 [10679188.001]
  • [Cites] Neurosurgery. 1994 Dec;35(6):1001-10; discussion 1010-1 [7885544.001]
  • [Cites] Pathol Int. 2001 Jul;51(7):543-8 [11472567.001]
  • [Cites] Virchows Arch. 2001 Dec;439(6):725-51 [11787845.001]
  • [Cites] J Neurosurg. 1995 Aug;83(2):206-14 [7616262.001]
  • [Cites] Mod Pathol. 2002 Dec;15(12):1357-65 [12481018.001]
  • (PMID = 15980970.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / Cytoskeletal Proteins; 0 / Trans-Activators; 0 / beta Catenin
  •  go-up   go-down


22. Bianco Ade M, Madeira LV, Rosemberg S, Shibata MK: Cortical seeding of a craniopharyngioma after craniotomy: Case report. Surg Neurol; 2006 Oct;66(4):437-40; discussion 440
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cortical seeding of a craniopharyngioma after craniotomy: Case report.
  • BACKGROUND: Cortical seeding of a craniopharyngioma has been rarely reported.
  • We present a case that ectopically recurred along the tract of a previous surgical route.
  • METHODS: A 27-year-old woman presented earlier with a suprasellar craniopharyngioma.
  • A left frontotemporal craniotomy was done with subtotal resection of the tumor because it was strongly adhered to the optic chiasm.
  • Histopathology confirmed the diagnosis of craniopharyngioma.
  • Magnetic resonance imaging revealed a contrast-enhancing tumor with cystic and solid components on the left temporal lobe cortex.
  • The primary tumor bed was intact.
  • The patient was reoperated, and the temporal lobe tumor was totally removed.
  • Histologic studies showed an adamantinomatous craniopharyngioma.
  • CONCLUSIONS: Although craniopharyngiomas exhibit a benign histopathologic pattern, a total resection combined with careful inspection and irrigation of the surgical field is the optimal treatment for preventing local and ectopic recurrences.
  • [MeSH-major] Brain Neoplasms / secondary. Craniopharyngioma / secondary. Neoplasm Seeding. Pituitary Neoplasms / pathology. Temporal Lobe / pathology
  • [MeSH-minor] Adult. Craniotomy. Female. Humans. Magnetic Resonance Imaging. Neoplasm Recurrence, Local. Neurosurgical Procedures / methods. Neurosurgical Procedures / standards. Optic Chiasm / pathology. Optic Chiasm / physiopathology. Seizures / etiology. Seizures / physiopathology. Treatment Outcome. Vision, Low / etiology. Vision, Low / physiopathology

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17015135.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Tena-Suck ML, Ortiz-Plata A, Galán F, Sánchez A: Expression of epithelial cell adhesion molecule and pituitary tumor transforming gene in adamantinomatous craniopharyngioma and its correlation with recurrence of the tumor. Ann Diagn Pathol; 2009 Apr;13(2):82-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of epithelial cell adhesion molecule and pituitary tumor transforming gene in adamantinomatous craniopharyngioma and its correlation with recurrence of the tumor.
  • Craniopharyngiomas are benign tumors of the sellar region generally associated with endocrine disorders and often locally aggressive.
  • The reliable criteria for predicting the tumor behavior are still lacking.
  • It has been suggested that proliferative potential of the tumor cells is necessary for recurrence.
  • The aim of this study was to evaluate the activity and correlation of epithelial cell adhesion molecule (Ep-CAM) and pituitary tumor transforming gene (PTTG-1) immunoexpression that is possibly related to relapse in 40 patients with adamantinomatous craniopharyngioma.
  • The PTGG-1 expression in craniopharyngioma may suggest hypophyseal metaplasia.
  • The Ep-CAM and PTTG-1 expression in craniopharyngioma could be used as prediction markers of relapsing tumor.
  • It has been suggested that proliferative potential of the tumor cells is necessary for recurrence.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. Cell Adhesion Molecules / biosynthesis. Craniopharyngioma / metabolism. Neoplasm Proteins / biosynthesis. Neoplasm Recurrence, Local / metabolism. Pituitary Neoplasms / metabolism
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Female. Gene Expression. Humans. Immunohistochemistry. Male. Securin

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Diagn Pathol. 2009 Dec;13(6):428-9 [19917481.001]
  • (PMID = 19302955.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human; 0 / Neoplasm Proteins; 0 / Securin; 0 / pituitary tumor-transforming protein 1, human
  •  go-up   go-down


24. Hölsken A, Buchfelder M, Fahlbusch R, Blümcke I, Buslei R: Tumour cell migration in adamantinomatous craniopharyngiomas is promoted by activated Wnt-signalling. Acta Neuropathol; 2010 May;119(5):631-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumour cell migration in adamantinomatous craniopharyngiomas is promoted by activated Wnt-signalling.
  • Activating beta-catenin mutations with aberrant cytoplasmic and nuclear protein accumulation are hallmarks of adamantinomatous craniopharyngiomas (adaCP).
  • [MeSH-major] Cell Movement / physiology. Craniopharyngioma / pathology. Pituitary Neoplasms / pathology. Signal Transduction / physiology. Wnt Proteins / genetics

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20131060.001).
  • [ISSN] 1432-0533
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Microfilament Proteins; 0 / RNA, Small Interfering; 0 / Wnt Proteins; 0 / beta Catenin; 146808-54-0 / fascin
  •  go-up   go-down


25. Hölsken A, Kreutzer J, Hofmann BM, Hans V, Oppel F, Buchfelder M, Fahlbusch R, Blümcke I, Buslei R: Target gene activation of the Wnt signaling pathway in nuclear beta-catenin accumulating cells of adamantinomatous craniopharyngiomas. Brain Pathol; 2009 Jul;19(3):357-64

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Target gene activation of the Wnt signaling pathway in nuclear beta-catenin accumulating cells of adamantinomatous craniopharyngiomas.
  • Activating beta-catenin (CTNNB1) mutations can be identified in the majority of adamantinomatous craniopharyngiomas (adaCP), suggesting an aberrant Wnt signaling pathway in this histopathologically peculiar tumor entity.
  • We performed a laser-microdissection-based study comparing beta-catenin accumulating vs. non-accumulating tumor cells.
  • Mutational analysis and gene expression profiling using real-time polymerase chain reaction were conducted in adamantinomatous and papillary tumor specimens.
  • Target gene activation, that is, over-expression of Axin2 could be detected in adaCP, especially in tumor cells with nuclear beta-catenin accumulation.
  • Interestingly, accumulating and non-accumulating tumor cell populations carried CTNNB1 mutations within exon 3.
  • [MeSH-major] Craniopharyngioma / genetics. Signal Transduction / physiology. Transcriptional Activation. Wnt Proteins / metabolism. beta Catenin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18540944.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / AXIN2 protein, human; 0 / Axin Protein; 0 / Bone Morphogenetic Protein 4; 0 / Cytoskeletal Proteins; 0 / Wnt Proteins; 0 / beta Catenin
  •  go-up   go-down


26. Burghaus S, Hölsken A, Buchfelder M, Fahlbusch R, Riederer BM, Hans V, Blümcke I, Buslei R: A tumor-specific cellular environment at the brain invasion border of adamantinomatous craniopharyngiomas. Virchows Arch; 2010 Mar;456(3):287-300
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A tumor-specific cellular environment at the brain invasion border of adamantinomatous craniopharyngiomas.
  • Craniopharyngiomas (CP) are benign epithelial tumors of the sellar region and can be clinicopathologically distinguished into adamantinomatous (adaCP) and papillary (papCP) variants.
  • Herein, we characterized the cellular interface between the tumor and the surrounding brain tissue in 48 CP (41 adaCP and seven papCP) compared to non-neuroepithelial tumors, i.e., 12 cavernous hemangiomas, 10 meningiomas, and 14 metastases using antibodies directed against glial fibrillary acid protein (GFAP), vimentin, nestin, microtubule-associated protein 2 (MAP2) splice variants, and tenascin-C.
  • We identified a specific cell population characterized by the coexpression of nestin, MAP2, and GFAP within the invasion niche of the adamantinomatous subtype.
  • Furthermore, the outer tumor cell layer of adaCP showed a distinct expression of MAP2, a novel finding helpful in the differential diagnosis of epithelial tumors in the sellar region.
  • Our data support the hypothesis that adaCP, unlike other non-neuroepithelial tumors of the central nervous system, create a tumor-specific cellular environment at the tumor-brain junction.
  • [MeSH-major] Craniopharyngioma / pathology. Pituitary Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Brain / metabolism. Child. Child, Preschool. Female. Gene Expression Regulation, Neoplastic. Glial Fibrillary Acidic Protein / metabolism. Humans. Intermediate Filament Proteins / metabolism. Male. Microtubule-Associated Proteins / metabolism. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Invasiveness / physiopathology. Neoplasm Metastasis / pathology. Neoplasm Metastasis / physiopathology. Nerve Tissue Proteins / metabolism. Nestin. Tenascin / metabolism. Vimentin / metabolism

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1595-603 [17122517.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):1997-2001 [12466115.001]
  • [Cites] Neuropathol Appl Neurobiol. 2002 Dec;28(6):480-8 [12445164.001]
  • [Cites] Endocr Rev. 2006 Jun;27(4):371-97 [16543382.001]
  • [Cites] J Pathol. 2004 Jul;203(3):814-21 [15221941.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 May;7(5):675-87 [17492931.001]
  • [Cites] Nat Cell Biol. 2001 Sep;3(9):778-84 [11533656.001]
  • [Cites] Brain Res. 2002 Jul 12;943(2):174-80 [12101039.001]
  • [Cites] Acta Neurochir (Wien). 2008 Dec;150(12):1213-26 [19002375.001]
  • [Cites] Oncogene. 2005 Dec 8;24(55):8200-4 [16091738.001]
  • [Cites] Glia. 2000 Feb 1;29(3):233-45 [10642750.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3897-904 [8033113.001]
  • [Cites] Acta Neuropathol. 2004 Aug;108(2):89-96 [15146346.001]
  • [Cites] Acta Neuropathol. 2005 Jun;109(6):589-97 [15891929.001]
  • [Cites] Brain Res Dev Brain Res. 2002 Nov 15;139(1):9-17 [12414089.001]
  • [Cites] J Neurochem. 1999 Dec;73(6):2531-7 [10582615.001]
  • [Cites] Glia. 1997 Jan;19(1):35-46 [8989566.001]
  • [Cites] J Biol Chem. 1990 Nov 15;265(32):19679-84 [2174050.001]
  • [Cites] Neurosurgery. 2005 Apr;56(4):763-76 [15792515.001]
  • [Cites] Brain Res Dev Brain Res. 1992 Feb 21;65(2):259-67 [1373996.001]
  • [Cites] Acta Neuropathol. 1978 Sep 15;43(3):191-203 [696237.001]
  • [Cites] Brain Pathol. 2009 Jul;19(3):357-64 [18540944.001]
  • [Cites] Pediatr Neurosurg. 1996 Nov;25(5):240-6; discussion 247 [9309787.001]
  • [Cites] Brain Res Dev Brain Res. 1992 Jul 24;68(1):111-23 [1521317.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):10894-8 [7479905.001]
  • [Cites] J Cell Sci. 1994 Nov;107 ( Pt 11):3115-25 [7699010.001]
  • [Cites] Cell Tissue Res. 2003 Dec;314(3):315-24 [14523640.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] J Neurosurg. 2007 Jan;106(1 Suppl):3-12 [17233305.001]
  • [Cites] Matrix Biol. 2001 Feb;20(1):13-22 [11246000.001]
  • [Cites] J Neurosurg. 1999 Feb;90(2):237-50 [9950494.001]
  • [Cites] J Neurosurg. 1988 Aug;69(2):155-70 [3292716.001]
  • [Cites] Eur J Endocrinol. 2005 Apr;152(4):557-67 [15817911.001]
  • [Cites] J Neurosurg. 1990 Jul;73(1):12-7 [2352012.001]
  • [Cites] Horm Res. 2008;69(4):193-202 [18204266.001]
  • [Cites] Curr Drug Targets CNS Neurol Disord. 2005 Feb;4(1):85-92 [15723616.001]
  • [Cites] Lab Invest. 2002 Mar;82(3):345-51 [11896213.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Apr;62(4):397-409 [15807869.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Oct;60(10):984-93 [11589429.001]
  • [Cites] Annu Rev Cell Biol. 1989;5:71-92 [2480799.001]
  • [Cites] Curr Opin Pediatr. 2007 Aug;19(4):471-9 [17630614.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Sep;82(17):6006-9 [3898077.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11771-80 [17178873.001]
  • [Cites] Glia. 1995 Apr;13(4):233-54 [7615335.001]
  • [Cites] Dev Dyn. 2004 May;230(1):1-11 [15108304.001]
  • [Cites] Brain Tumor Pathol. 2005;22(2):75-8 [18095108.001]
  • [Cites] J Neurosurg. 1998 Oct;89(4):547-51 [9761047.001]
  • [Cites] Eur J Neurosci. 2005 Oct;22(8):1863-72 [16262626.001]
  • [Cites] Pituitary. 2005;8(2):75-9 [16195780.001]
  • [Cites] Neurosurgery. 1994 Dec;35(6):1001-10; discussion 1010-1 [7885544.001]
  • [Cites] Acta Neuropathol. 2007 May;113(5):585-90 [17221204.001]
  • [Cites] Brain Res Dev Brain Res. 2002 Mar 31;134(1-2):87-92 [11947939.001]
  • [Cites] Cell. 1990 Feb 23;60(4):585-95 [1689217.001]
  • [Cites] Exp Neurol. 1999 Dec;160(2):348-60 [10619552.001]
  • [Cites] Eur J Endocrinol. 2008 Dec;159 Suppl 1:S95-9 [18775978.001]
  • [Cites] J Pediatr Endocrinol Metab. 2006 Apr;19 Suppl 1:453-4 [16700324.001]
  • [Cites] Cancer. 2003 Dec 1;98(11):2430-9 [14635078.001]
  • [Cites] J Neurosurg. 1995 Aug;83(2):206-14 [7616262.001]
  • [Cites] Neuropathology. 2007 Feb;27(1):1-9 [17319278.001]
  • (PMID = 20069432.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein; 0 / Intermediate Filament Proteins; 0 / Microtubule-Associated Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / Tenascin; 0 / Vimentin
  •  go-up   go-down


27. Lefranc F, Mijatovic T, Decaestecker C, Kaltner H, André S, Brotchi J, Salmon I, Gabius HJ, Kiss R: Monitoring the expression profiles of integrins and adhesion/growth-regulatory galectins in adamantinomatous craniopharyngiomas: their ability to regulate tumor adhesiveness to surrounding tissue and their contribution to prognosis. Neurosurgery; 2005 Apr;56(4):763-76
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monitoring the expression profiles of integrins and adhesion/growth-regulatory galectins in adamantinomatous craniopharyngiomas: their ability to regulate tumor adhesiveness to surrounding tissue and their contribution to prognosis.
  • OBJECTIVE: The purpose of this study was to identify biological markers that may be involved in the adhesiveness of craniopharyngiomas to optical chiasms and/or pituitary stalks.
  • METHODS: We determined the complete pattern of integrin expression in three craniopharyngiomas by means of a complementary deoxyribonucleic acid microarray.
  • We also quantitatively (computer-assisted microscopy) determined the levels of immunohistochemical expression of galectin-1, -3, -4, -7, and -8 in 50 adamantinomatous craniopharyngiomas.
  • RESULTS: The present study shows that at both the ribonucleic acid and protein levels, adamantinomatous craniopharyngiomas express the alpha2, alpha6, alpha(v), beta1, beta5, and beta8 integrin subunits, whereas optical chiasms and pituitary stalks express vitronectin, thrombospondin, and various forms of collagens.
  • CONCLUSION: Our data suggest that at least part of the adhesiveness of craniopharyngiomas to the surrounding tissue, such as optical chiasms and pituitary stalks, could be explained by the interactions between alpha(2beta1) integrin expressed by craniopharyngiomas and collagens on the one hand, and vitronectin expressed by the surrounding tissue on the other hand.
  • [MeSH-major] Craniopharyngioma / genetics. Galectins / genetics. Gene Expression Profiling. Integrins / genetics. Pituitary Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15792515.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Galectins; 0 / Integrins; 0 / RNA, Messenger
  •  go-up   go-down


28. Okada T, Fujitsu K, Miyahara K, Ichikawa T, Takemoto Y, Niino H, Yagishita S, Shiina T: Ciliated craniopharyngioma--case report and pathological study. Acta Neurochir (Wien); 2010 Feb;152(2):303-6; discussion 307
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ciliated craniopharyngioma--case report and pathological study.
  • BACKGROUND: Craniopharyngioma has two subtypes: adamantinomatous and squamous-papillary.
  • Squamous-papillary craniopharyngioma may develop from remnants of the craniopharyngeal duct, anterior pituitary cells with squamous metaplasia, suprasellar epidermoid cyst, or Rathke cleft cyst.
  • AIM: While ciliated craniopharyngioma is considered to represent a transitional stage between Rathke cleft cyst and squamous-papillary craniopharyngioma, ciliated craniopharyngioma following Rathke cleft cyst at the same site has not previously been described.
  • RESULTS: We report a case of ciliated craniopharyngioma developing from Rathke cleft cyst.
  • CONCLUSION: The clinical course for this case is discussed together with a review of the pathological literature for ciliated craniopharyngioma.
  • [MeSH-major] Central Nervous System Cysts / complications. Central Nervous System Cysts / pathology. Craniopharyngioma / etiology. Craniopharyngioma / pathology. Pituitary Gland / pathology. Pituitary Neoplasms / pathology
  • [MeSH-minor] Cell Transformation, Neoplastic / pathology. Cerebrospinal Fluid Rhinorrhea / etiology. Cerebrospinal Fluid Rhinorrhea / pathology. Cerebrospinal Fluid Rhinorrhea / surgery. Cilia / pathology. Craniotomy. Epithelial Cells / pathology. Hemianopsia / etiology. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / prevention & control. Neoplasm Recurrence, Local / surgery. Neurosurgical Procedures. Optic Chiasm / pathology. Pituitary Hormones / blood. Pituitary Hormones / secretion. Postoperative Complications / etiology. Postoperative Complications / pathology. Postoperative Complications / surgery. Reoperation. Sella Turcica / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19626269.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Pituitary Hormones
  •  go-up   go-down


29. Park YS, Ahn JY, Kim DS, Kim TS, Kim SH: Late development of craniopharyngioma following surgery for Rathke's cleft cyst. Clin Neuropathol; 2009 May-Jun;28(3):177-81
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late development of craniopharyngioma following surgery for Rathke's cleft cyst.
  • OBJECTIVE: Rathke's cleft cyst (RCC) may transform to papillary type craniopharyngioma (CP) after squamous metaplasia: this is referred to as ciliated CP.
  • We encountered a case involving a patient who had late development of adamantinomatous CP following surgery for RCC, the details of which may shed light on the histogenesis of CP in general.
  • 34 months after the initial surgery, the patient revisited our hospital for a rapidly aggravating visual disturbance and underwent neuroendoscopic biopsy and tumor removal via a bifrontal craniotomy.
  • Histologically, the tumor was shown to be an adamantinomatous CP.
  • CONCLUSIONS: Our case of adamantinomatous CP that developed long after removal of the RCC, diagnosed by beta-catenin staining, supports the hypothesis that CPs may develop from RCCs directly due to beta-catenin mutations.
  • [MeSH-major] Central Nervous System Cysts / pathology. Craniopharyngioma / pathology. Neoplasms, Second Primary / pathology. Pituitary Neoplasms / pathology

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19537134.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / beta Catenin
  •  go-up   go-down


30. Kusama K, Katayama Y, Oba K, Ishige T, Kebusa Y, Okazawa J, Fukushima T, Yoshino A: Expression of hard alpha-keratins in pilomatrixoma, craniopharyngioma, and calcifying odontogenic cyst. Am J Clin Pathol; 2005 Mar;123(3):376-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of hard alpha-keratins in pilomatrixoma, craniopharyngioma, and calcifying odontogenic cyst.
  • To examine the properties of shadow and ghost cells, 3 kinds of antibodies were raised against human hair proteins and their immunoreactivity was examined in tumors expressing those cells: pilomatrixoma, 14 cases; craniopharyngioma, 17 cases; and calcifying odontogenic cyst (COC), 14 cases.
  • Positive reactions were found only in shadow cells of all 13 adamantinomatous craniopharyngiomas.
  • [MeSH-major] Craniopharyngioma / metabolism. Hair Diseases / metabolism. Keratins / metabolism. Neoplasm Proteins / metabolism. Neoplasms / metabolism. Odontogenic Cyst, Calcifying / metabolism. Pilomatrixoma / metabolism
  • [MeSH-minor] Animals. Biomarkers, Tumor / immunology. Biomarkers, Tumor / metabolism. Blotting, Western. Cells, Cultured. Hair / chemistry. Humans. Hybridomas. Immunoenzyme Techniques. Jaw Neoplasms / metabolism. Jaw Neoplasms / pathology. Mice. Mice, Inbred BALB C. Pituitary Neoplasms / metabolism. Pituitary Neoplasms / pathology. Skin Neoplasms / metabolism. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • Genetic Alliance. consumer health - Pilomatrixoma.
  • MedlinePlus Health Information. consumer health - Hair Problems.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15716233.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


31. Buslei R, Nolde M, Hofmann B, Meissner S, Eyupoglu IY, Siebzehnrübl F, Hahnen E, Kreutzer J, Fahlbusch R: Common mutations of beta-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region. Acta Neuropathol; 2005 Jun;109(6):589-97
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Common mutations of beta-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region.
  • Here, we examined beta-catenin and adenomatous polyposis coli (APC) by mutational analysis in pituitary adenomas (n=60) and a large series of craniopharyngiomas (n=41).
  • Furthermore, the expression pattern of beta-catenin was immunohistochemically analysed in a cohort of tumours and cysts of the sellar region including pituitary adenomas (n=58), craniopharyngiomas (n=57), arachnoidal cysts (n=8), Rathke's cleft cysts (n=10) and xanthogranulomas (n=6).
  • Whereas APC mutations were not detectable in any tumour entity, beta-catenin mutations were present in 77% of craniopharyngiomas, exclusively of the adamantinomatous subtype.
  • Immunohistochemical analysis confirmed a shift from membrane-bound to nuclear accumulation of beta-catenin in 94% of the adamantinomatous tumours.
  • We conclude that beta-catenin mutations and/or nuclear accumulation serve as diagnostic hallmarks of the adamantinomatous variant, setting it apart from the papillary variant of craniopharyngioma.
  • [MeSH-major] Craniopharyngioma / genetics. Cytoskeletal Proteins / genetics. Genes, APC. Pituitary Neoplasms / genetics. Sella Turcica / pathology. Trans-Activators / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15891929.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / Cytoskeletal Proteins; 0 / Trans-Activators; 0 / beta Catenin
  •  go-up   go-down


32. Wang XY, Xu SJ, Li XG: Post-operative implantation metastasis of craniopharyngioma: a case report. J Int Med Res; 2010 Sep-Oct;38(5):1876-82
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-operative implantation metastasis of craniopharyngioma: a case report.
  • Craniopharyngiomas are histologically benign epithelial tumours arising from squamous epithelial remnants of Rathke's pouch, which have a tendency to invade surrounding structures and recur after apparently complete resection.
  • Total resection of a craniopharyngioma may be difficult, and recurrence has been reported in 25-70% of patients.
  • Here a case of metastatic adamantinomatous-type craniopharyngioma attributed to direct implantation by surgical procedure is presented, along with a review of the current literature on craniopharyngiomas.
  • [MeSH-major] Craniopharyngioma / secondary. Neoplasm Recurrence, Local / pathology. Pituitary Neoplasms / pathology

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21309505.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


33. Tena-Suck ML, Moreno-Reyes I, Rembao D, Vega R, Moreno-Jiménez S, Castillejos-López Mde J, Fernández-Plata R, Martínez-Briseño D, Salinas-Lara C: [Clinical pathological study of craniopharyngioma. Fifteen years at the National Institute of Neurology and Neurosurgery "Manuel Velasco Suárez"]. Gac Med Mex; 2009 Sep-Oct;145(5):361-8
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical pathological study of craniopharyngioma. Fifteen years at the National Institute of Neurology and Neurosurgery "Manuel Velasco Suárez"].
  • [Transliterated title] Craneofaringioma, estudio clínico-patológico. Quince años del Instituto Nacional de Neurología y Neurocirugía "Manuel Velasco Suárez".
  • BACKGROUND: Craniopharyngioma is a sellar region benign cyst It's frequency ranges from 1.2% to 4.6% of all brain tumors.
  • OBJECTIVE: To carry out a clinical pathological correlation of craniopharyngioma among adults and describe the tumor's biological characteristics.
  • METHODS: We included 115 craniopharyngiomas; 100 were adamantimomatous and 15 were papillary type.
  • RESULTS: We noted a recurrence among 50 patients (43%), of which 5/15 were papillary and 45/100 adamantinomatous.
  • Follow-up was longer among females than males and in suprasellar tumor location, papillary type, external epithelium cysts and laxo stellate reticulum.
  • CONCLUSIONS: However a good prognostic factor in craniopharyngiomas was observed in older female patients with complete exeresis, small tumors, external epithelium cysts, edematous stroma, inflammation, and absence of atypical cell and mitosis.
  • [MeSH-major] Craniopharyngioma / pathology. Pituitary Neoplasms / pathology

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20073441.001).
  • [ISSN] 0016-3813
  • [Journal-full-title] Gaceta médica de México
  • [ISO-abbreviation] Gac Med Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


34. Yoshida A, Sen C, Asa SL, Rosenblum MK: Composite pituitary adenoma and craniopharyngioma?: an unusual sellar neoplasm with divergent differentiation. Am J Surg Pathol; 2008 Nov;32(11):1736-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Composite pituitary adenoma and craniopharyngioma?: an unusual sellar neoplasm with divergent differentiation.
  • The patient was treated with thyroid radioablation and hormone replacement and followed for 7 years, during which time the tumor grew to 4.6 cm.
  • At transsphenoidal surgery, a tumor consisting of a pituitary adenoma and adamantinomatous craniopharyngiomalike components was resected.
  • Both components were closely intermingled, but there was no evidence of an intermediate morphologic phenotype.
  • This lesion may represent an unusual composite tumor attributable to divergent differentiation of a common precursor.
  • [MeSH-major] Adenoma / pathology. Craniopharyngioma / pathology. Neoplasms, Multiple Primary / pathology. Pituitary Neoplasms / pathology

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18769335.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-71-5 / Thyrotropin
  •  go-up   go-down


35. Karavitaki N, Cudlip S, Adams CB, Wass JA: Craniopharyngiomas. Endocr Rev; 2006 Jun;27(4):371-97
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Craniopharyngiomas.
  • Craniopharyngiomas are rare, mainly sellar/parasellar, epithelial tumors diagnosed during childhood or adult life.
  • Histologically, two primary subtypes have been recognized (adamantinomatous and papillary) with an as yet, unclarified pathogenesis.
  • Currently, surgical excision followed by external beam irradiation, in cases of residual tumor, is the main treatment option.
  • [MeSH-major] Craniopharyngioma / therapy. Pituitary Neoplasms / therapy
  • [MeSH-minor] Antibiotics, Antineoplastic / therapeutic use. Bleomycin / adverse effects. Bleomycin / therapeutic use. Cognition Disorders / etiology. Humans. Hypothalamic Diseases / etiology. Neoplasm Recurrence, Local / etiology. Radiotherapy / adverse effects. Radiotherapy / methods

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16543382.001).
  • [ISSN] 0163-769X
  • [Journal-full-title] Endocrine reviews
  • [ISO-abbreviation] Endocr. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin
  • [Number-of-references] 256
  •  go-up   go-down


36. Sun HI, Akgun E, Bicer A, Ozkan A, Bozkurt SU, Kurtkaya O, Koc DY, Pamir MN, Kilic T: Expression of angiogenic factors in craniopharyngiomas: implications for tumor recurrence. Neurosurgery; 2010 Apr;66(4):744-50; discussion 750
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of angiogenic factors in craniopharyngiomas: implications for tumor recurrence.
  • BACKGROUND: The primary treatment for craniopharyngiomas is total excision, but recurrence is common.
  • OBJECTIVE: We hypothesized that recurrence is linked to the angiogenesis of the tumor.
  • Recurrent and nonrecurrent tumor samples were compared with regard to expression of angiogenesis-related factors and angiogenic capacity in a corneal angiogenesis model.
  • METHODS: Specimens of 4 recurrent and 6 nonrecurrent tumors were selected from 57 patients with adamantinomatous craniopharyngiomas.
  • CONCLUSION: These findings suggest a relationship between recurrence of craniopharyngiomas and angiogenesis.
  • New treatment modalities with selective PDGFR-alpha blockers may represent a novel and effective therapeutic option for the treatment of craniopharyngiomas.
  • [MeSH-major] Angiogenesis Inducing Agents / metabolism. Craniopharyngioma / metabolism. Gene Expression Regulation, Neoplastic / physiology. Neoplasm Recurrence, Local / metabolism. Pituitary Neoplasms / metabolism
  • [MeSH-minor] Adult. Animals. Cornea / metabolism. Cornea / pathology. Disease Models, Animal. Female. Fibroblast Growth Factor 2 / metabolism. Fibronectins / metabolism. Humans. Male. Middle Aged. Neoplasm Transplantation. Platelet-Derived Growth Factor / metabolism. Rats. Rats, Sprague-Dawley. Retrospective Studies. Statistics, Nonparametric. Time Factors. Vascular Endothelial Growth Factor A / metabolism. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20190664.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inducing Agents; 0 / Fibronectins; 0 / Platelet-Derived Growth Factor; 0 / Vascular Endothelial Growth Factor A; 103107-01-3 / Fibroblast Growth Factor 2
  •  go-up   go-down


37. Tena-Suck ML, Salinas-Lara C, Arce-Arellano RI, Rembao-Bojórquez D, Morales-Espinosa D, Sotelo J, Arrieta O: Clinico-pathological and immunohistochemical characteristics associated to recurrence/regrowth of craniopharyngiomas. Clin Neurol Neurosurg; 2006 Oct;108(7):661-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinico-pathological and immunohistochemical characteristics associated to recurrence/regrowth of craniopharyngiomas.
  • BACKGROUND: Craniopharyngioma is a rare, benign epithelial brain tumor of the suprasellar region with a high rate of recurrence.
  • METHODS: We compared recurrence/regrowth of the tumors with the clinico-pathological characteristics, vascular density, cell proliferation index, and immunohistochemical profile (cytokeratins, epithelial membrane antigen [EMA], carcinoembrionary antigen [CEA], and laminin) of 47 patients with craniopharyngioma followed for more than 5 years.
  • RESULTS: Tumors were adamantinomatous in 42 cases (89%) and papillary squamous in 5 cases (11%).
  • The cell proliferation index and vascular density were greater in adamantinomatous than in papillary tumors (22+/-6 versus 17+/-3, p=0.05; and 21+/-3 versus 17+/-3, p=0.037, respectively); they were neither related to recurrence nor to regrowth.
  • No significant differences were found between adamantinomatous and papillary tumors regarding the presence of cytokeratin, laminin, CEA or glial fibrillary acidic protein (GFAP).
  • Residual tumor after surgery, whorl-like arrays (p=0.04) and immunoreactivity for p53 (p=0.022) were significantly related to recurrence/regrowth.
  • CONCLUSIONS: Residual tumor after surgery, immunoreactivity to p53 and presence of whorl-like arrays are associated to recurrence/regrowth of craniopharyngioma.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / physiopathology. Craniopharyngioma / diagnosis. Craniopharyngioma / physiopathology. Neoplasm Recurrence, Local / epidemiology
  • [MeSH-minor] Adult. Biomarkers, Tumor / metabolism. Carcinoembryonic Antigen / metabolism. Cell Proliferation. Epithelial Cells / metabolism. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry. Keratins / metabolism. Laminin / metabolism. Male. Mucin-1 / metabolism. Neovascularization, Pathologic / diagnosis. Neovascularization, Pathologic / epidemiology. Neovascularization, Pathologic / physiopathology. Predictive Value of Tests. Prognosis. Radiotherapy / statistics & numerical data. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16500745.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Laminin; 0 / Mucin-1; 0 / Tumor Suppressor Protein p53; 68238-35-7 / Keratins
  •  go-up   go-down


38. Buslei R, Hölsken A, Hofmann B, Kreutzer J, Siebzehnrubl F, Hans V, Oppel F, Buchfelder M, Fahlbusch R, Blümcke I: Nuclear beta-catenin accumulation associates with epithelial morphogenesis in craniopharyngiomas. Acta Neuropathol; 2007 May;113(5):585-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear beta-catenin accumulation associates with epithelial morphogenesis in craniopharyngiomas.
  • Adamantinomatous craniopharyngiomas carry activating mutations in exon 3 of the beta-catenin gene, which results in a distinct pattern of nuclear beta-catenin accumulation in up to 95% of respective tumour specimens.
  • To better characterise the impact of nuclear beta-catenin aggregation in these neoplasms, we systematically examined epithelial differentiation and cell cycle-associated molecules in accumulating compared to non-accumulating tumour cell clusters using a cohort of 65 adamantinomatous craniopharyngiomas.
  • Our data support an impact of nuclear beta-catenin on different cytoarchitectural and epithelial differentiation patterns in adamantinomatous craniopharyngiomas.
  • [MeSH-major] Craniopharyngioma / metabolism. Craniopharyngioma / pathology. Epithelium / growth & development. Morphogenesis / physiology. beta Catenin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17221204.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Keratin-18; 0 / Keratin-8; 0 / beta Catenin
  •  go-up   go-down


39. Agozzino L, Ferraraccio F, Accardo M, Esposito S, Agozzino M, Cuccurullo L: Morphological and ultrastructural findings of prognostic impact in craniopharyngiomas. Ultrastruct Pathol; 2006 May-Jun;30(3):143-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphological and ultrastructural findings of prognostic impact in craniopharyngiomas.
  • Craniopharyngioma is a slow-growing epithelial tumor with an unpredictable tendency to recur.
  • All the tumors were surgically excised and all recurrences exhibited an adamantinomatous pattern; mitotic rate was low (< 5 x 10 HPF) in both recurrent and in nonrecurrent tumors.
  • The MIB-1 Labelling Index was: 22.12% in primary tumors, 27.5% in recurrences, 31.3% in adult nonrecurrent tumors, and 4.1% in the pediatric tumor.
  • Lack of clear correlations between morphological or immuno-staining patterns and behavior suggests that these features have no prognostic value in adult as well as in pediatric craniopharyngiomas.
  • In this study, the only results that may be related to the aggressiveness of tumor is the major vascularization in the recurrent tumors in which the vessels show also ultrastructural changes.
  • [MeSH-major] Craniopharyngioma / pathology. Pituitary Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / analysis. Child. Child, Preschool. Cytoplasm / ultrastructure. Endothelium, Vascular / ultrastructure. Epithelial Cells / ultrastructure. Female. Humans. Ki-67 Antigen / analysis. Male. Microscopy, Electron, Transmission. Middle Aged. Neoplasm Recurrence, Local. Proliferating Cell Nuclear Antigen / analysis. Vascular Endothelial Growth Factor A / analysis

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16825115.001).
  • [ISSN] 1521-0758
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


40. Vidal S, Scheithauer BW, Kovacs K, Lloyd RV: Angiogenesis and the growth potential of craniopharyngiomas. Endocr Pathol; 2005;16(3):219-28
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenesis and the growth potential of craniopharyngiomas.
  • The present study was performed to evaluate the role of neovascularization on the behavior of craniopharyngiomas as well as the contribution of endothelial cell proliferation and migration in the remodeling and expansion of the vascular network associated with angiogenesis.
  • Fourteen primary tumors were studied, all of the adamantinomatous type.
  • Immunohistochemistry demonstrated that integrin alphavbeta3 expression was restricted to tumor vasculature; the tumor cells were immunonegative.
  • More studies are needed to assess whether integrin alphavbeta3 antagonists or drugs that arrest the cell cycle of endothelial cells can inhibit angiogenesis in craniopharyngiomas.
  • [MeSH-major] Craniopharyngioma / blood supply. Neovascularization, Pathologic / pathology. Pituitary Neoplasms / blood supply
  • [MeSH-minor] Adolescent. Antigens, CD34 / metabolism. Biomarkers, Tumor / metabolism. Cell Count. Child. Child, Preschool. Female. Humans. Immunoenzyme Techniques. Integrin alphaVbeta3 / metabolism. Ki-67 Antigen / metabolism. Male. Microcirculation. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1994 Apr 22;264(5158):569-71 [7512751.001]
  • [Cites] J Pathol. 1997 Sep;183(1):39-43 [9370945.001]
  • [Cites] Cancer. 1996 Mar 15;77(6):1161-6 [8635139.001]
  • [Cites] J Neurosurg. 1999 Nov;91(5):831-4 [10541241.001]
  • [Cites] Neuropediatrics. 2001 Apr;32(2):75-9 [11414647.001]
  • [Cites] Childs Nerv Syst. 2001 Sep;17(9):531-6; discussion 537 [11585327.001]
  • [Cites] Folia Neuropathol. 1999;37(3):179-84 [10581855.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6624-8 [11559524.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2232-8 [11280792.001]
  • [Cites] Adv Anat Pathol. 2002 Jan;9(1):24-36 [11756757.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1382-90 [10334522.001]
  • [Cites] Circ Res. 1999 Aug 6;85(3):221-8 [10436164.001]
  • [Cites] Neuro Oncol. 2002 Apr;4(2):123-8 [11916504.001]
  • [Cites] Histopathology. 2001 Oct;39(4):409-15 [11683943.001]
  • [Cites] J Hematother Stem Cell Res. 2002 Apr;11(2):171-8 [11983091.001]
  • [Cites] Cell. 1994 Dec 30;79(7):1157-64 [7528107.001]
  • [Cites] Mod Pathol. 1995 Sep;8(7):745-52 [8539232.001]
  • [Cites] Ann Oncol. 1995 Jan;6(1):59-64 [7536030.001]
  • [Cites] Oncol Rep. 1999 Jul-Aug;6(4):839-42 [10373667.001]
  • [Cites] Neurosurgery. 1996 Jan;38(1):99-106; discussion 106-7 [8747957.001]
  • [Cites] Cell. 1991 Jan 25;64(2):327-36 [1703045.001]
  • [Cites] Endocr Pathol. 2003 Fall;14(3):239-47 [14586069.001]
  • [Cites] Adv Exp Med Biol. 2000;476:169-80 [10949664.001]
  • [Cites] Neurosurgery. 2001 Aug;49(2):380-9; discussion 390 [11504114.001]
  • [Cites] Virchows Arch. 2001 Jun;438(6):595-602 [11469692.001]
  • [Cites] Int J Cancer. 2002 Feb 20;97(6):839-45 [11857365.001]
  • [Cites] Mod Pathol. 2001 Nov;14(11):1126-32 [11706074.001]
  • [Cites] Pediatr Neurosurg. 2000 Oct;33(4):211-8 [11124639.001]
  • [Cites] Cancer J. 2001 Nov-Dec;7(6):516-20 [11769865.001]
  • [Cites] Lab Invest. 1995 Dec;73(6):844-50 [8558846.001]
  • [Cites] Clin Cancer Res. 1998 Nov;4(11):2625-34 [9829725.001]
  • [Cites] Science. 2002 Jun 28;296(5577):2404-7 [12089446.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 Jun;75(6):889-92 [15146007.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):362-72 [8625246.001]
  • [Cites] Cancer. 2002 Feb 1;94(3):738-45 [11857307.001]
  • [Cites] Curr Opin Pharmacol. 2002 Aug;2(4):403-14 [12127873.001]
  • [Cites] Nat Med. 2002 Jan;8(1):27-34 [11786903.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8730-6 [11751392.001]
  • [Cites] Clin Neuropathol. 2003 Sep-Oct;22(5):229-34 [14531547.001]
  • [Cites] Int J Mol Med. 1999 Feb;3(2):157-61 [9917523.001]
  • [Cites] Curr Pharm Des. 2001 Nov;7(16):1553-80 [11562299.001]
  • [Cites] Childs Nerv Syst. 2001 Oct;17(10):577-83 [11685518.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4353-61 [15705795.001]
  • [Cites] J Endocrinol. 2000 Jul;166(1):95-101 [10856887.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 May 1;44(2):255-63 [10760417.001]
  • [Cites] Surg Neurol. 2000 Sep;54(3):241-7; discussion 248 [11118571.001]
  • [Cites] Anticancer Res. 1997 Nov-Dec;17(6D):4747-53 [9494601.001]
  • (PMID = 16299405.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / Integrin alphaVbeta3; 0 / Ki-67 Antigen
  •  go-up   go-down


41. Qiu SJ, Guo YL, Zhang XL, Zhang F, Zhang YZ, Wen G, Hu BS: [Imaging findings of craniopharyngioma in relation to its surgical management: a retrospective analysis]. Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jul;27(7):980-2
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Imaging findings of craniopharyngioma in relation to its surgical management: a retrospective analysis].
  • Of the 123 craniopharyngioma patients, 59 were found to have adamantinous craniopharyngiomas, 41 had papillary squamous craniopharyngiomas, and 23 had mixed tumors.
  • Solid tumor was found in 18 cases, cystic tumor in 38 cases, and calcification in 78 cases; in 23 cases, the posterior of the tumor did not exhibit clear boundary from the wall of the three cerebral ventricles, and in 11 cases CT and MRI displayed hypophysial stalk, which was found intraoperatively in 53 cases.
  • CONCLUSIONS: MRI allows clear vision of the range of craniopharyngioma involvement and the anatomical structures surrounding the tumor.
  • Accurate identification of the site, dimension, calcification patterns and relation between the hypophysial stalk and hypothalamus by the imaging modalities significantly benefits the optimization of the surgical plan for the tumor.
  • [MeSH-major] Craniopharyngioma / diagnosis. Craniopharyngioma / surgery. Magnetic Resonance Imaging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17666331.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


42. Cao J, Lin JP, Yang LX, Chen K, Huang ZS: Expression of aberrant beta-catenin and impaired p63 in craniopharyngiomas. Br J Neurosurg; 2010 Jun;24(3):249-56
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of aberrant beta-catenin and impaired p63 in craniopharyngiomas.
  • Craniopharyngiomas are rare, histologically benign, non-neuroepithelial epithelial tumors arising from the sellar region, the molecular pathogenesis of CPs is yet not understood.
  • The aim of the present study was to assess expression of aberrant beta-catenin and impaired p63 in 66 craniopharyngiomas included 51 adamantinomatous craniopharyngiomas and 15 squamous papillary craniopharyngiomas.
  • On immunohistochemistry, 47 out of 51 adamantinomatous craniopharyngiomas, but not squamous papillary craniopharyngiomas, showed strong nuclear/cytoplasmic expression for beta-catenin predominantly in compactly cohesive epithelial cells within the whorl-like arrays where ki-67 was almost absent and rarely in palisaded cells where ki-67 was mainly present.
  • P63 overexpression was observed in 45 out of 51 adamantinomatous craniopharyngiomas and 14 out of 15 squamous papillary craniopharyngiomas.
  • P63 stained not only in the nuclei of basal layer cells but also within the whorl-like arrays in adamantinomatous craniopharyngiomas and uniformly in squamous papillary craniopharyngiomas.
  • [MeSH-major] Craniopharyngioma / metabolism. Membrane Proteins / metabolism. Pituitary Neoplasms / metabolism. beta Catenin / metabolism
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. DNA-Binding Proteins / metabolism. Female. Humans. Immunohistochemistry. Infant. Ki-67 Antigen / metabolism. Male. Middle Aged. RNA, Messenger / metabolism. Trans-Activators / metabolism. Transcription Factors. Tumor Suppressor Proteins / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20128632.001).
  • [ISSN] 1360-046X
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / beta Catenin
  •  go-up   go-down


43. [Craniopharyngiomas in the adults]. Arkh Patol; 2005 Jul-Aug;67(4):41-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Craniopharyngiomas in the adults].
  • Craniopharyngiomas (CP) were studied morphologically (52 cases), immunohistochemically (6 cases) and molecular-genetically (5 cases) in patients aged 18-65 years.
  • Proliferative activity (Ki-67) in CP is 11% in adamantinomatous CP and 2% in capillary CP and pronounced proliferation is observed around keratohyalin deposits.
  • [MeSH-major] Biomarkers, Tumor / analysis. Craniopharyngioma / diagnosis. Craniopharyngioma / mortality. Pituitary Neoplasms / diagnosis. Pituitary Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16209298.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


44. Kobayashi T: Treatment strategy and pathological background of radiosurgery for craniopharyngiomas. Prog Neurol Surg; 2007;20:180-91
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment strategy and pathological background of radiosurgery for craniopharyngiomas.
  • In this paper, pathological aspects of diagnosis, classification, treatment strategy and interstitial radiotherapy for craniopharyngiomas have been discussed and reviewed.
  • Two pathological patterns, adamantinomatous and squamous cell types, are well correlated to the age of the patient, nature and response of tumor to radiation therapy.
  • The originating portion of tumor (so called 'R site') at the retrochiasmal and anterior part of the stalk showed close contact of tumor with hypothalamic neurons without arachnoid membrane or glial cleavage.
  • This means that the total removal of the tumor is difficult without damage to the stalk and optic pathway.
  • A new concept of strategy can be proposed that a small tumor at this portion is intentionally left behind and is treated by gamma radiosurgery.
  • The treatment strategy for large cystic tumor has been important and two methods can be recommended.
  • [MeSH-major] Craniopharyngioma / pathology. Craniopharyngioma / surgery. Pituitary Neoplasms / pathology. Pituitary Neoplasms / surgery. Radiosurgery / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317986.001).
  • [ISSN] 0079-6492
  • [Journal-full-title] Progress in neurological surgery
  • [ISO-abbreviation] Prog Neurol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down






Advertisement